An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
Awad, Mark M
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). [electronic resource] - Lung cancer (Amsterdam, Netherlands) 02 2017 - 126-130 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
1872-8332
10.1016/j.lungcan.2016.12.019 doi
Administration, Intravenous
Adult
Aged
Cell Cycle Proteins--adverse effects
Disease-Free Survival
Female
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Protein Serine-Threonine Kinases--adverse effects
Proto-Oncogene Proteins--adverse effects
Pteridines--administration & dosage
Recurrence
Small Cell Lung Carcinoma--drug therapy
Smoking--epidemiology
Treatment Failure
Treatment Outcome
Polo-Like Kinase 1
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). [electronic resource] - Lung cancer (Amsterdam, Netherlands) 02 2017 - 126-130 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
1872-8332
10.1016/j.lungcan.2016.12.019 doi
Administration, Intravenous
Adult
Aged
Cell Cycle Proteins--adverse effects
Disease-Free Survival
Female
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Protein Serine-Threonine Kinases--adverse effects
Proto-Oncogene Proteins--adverse effects
Pteridines--administration & dosage
Recurrence
Small Cell Lung Carcinoma--drug therapy
Smoking--epidemiology
Treatment Failure
Treatment Outcome
Polo-Like Kinase 1